Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cel-Sci Corporation (CVM : AMEX)

• Company Description    CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $3.82 Daily Weekly Monthly 20 Day Moving Average: 265,175 shares Shares Outstanding: 3.03 (millions) Market Capitalization: $11.58 (millions) Beta: 0.30 52 Week High: $66.60 52 Week Low: $1.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 61.18% 55.15% 12 Week -50.08% -58.01% Year To Date -68.19% -70.21%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8229 BOONE BLVD . SUITE 802 - VIENNA,VA 22182 USA ph: 703-506-9460 fax: 703-506-9471 gdewindt@cel-sci.com http://www.cel-sci.com

• General Corporate Information    Officers Geert Kersten - Chief Executive Officer Robert Watson - Chairman Patricia Prichep - Chief Financial Officer and Chief Operations Offic Robert Watson - Director Mario Gobbo - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 150837706 SIC: 2836 Fiscal Year Fiscal Year End: September Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 3.03 Most Recent Split Date: 5.00 (0.03:1) Beta: 0.30 Market Capitalization: $11.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-8.71 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 42.86% vs. Previous Quarter: 27.27% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -268.36 12/31/24 - -238.05 ROA 06/30/25 - - 03/31/25 - -110.67 12/31/24 - -104.65 Current Ratio 06/30/25 - - 03/31/25 - 0.55 12/31/24 - 1.07 Quick Ratio 06/30/25 - - 03/31/25 - 0.39 12/31/24 - 0.91 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.86 12/31/24 - 4.58 Inventory Turnover 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.86 12/31/24 - 0.66 Debt-to-Capital 06/30/25 - - 03/31/25 - 46.13 12/31/24 - 39.59

Powered by Zacks Investment Research ©